Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

We want you to take advantage of everything Clinical Advisor has to offer. To view unlimited content, log in or register for free.

Semaglutide has already been approved to treat type 2 diabetes under the brand name Ozempic, and to treat obesity as Wegovy. © Michael Siluk/UCG/Universal Images ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Semaglutide and tirzepatide prescriptions for obesity are influenced by race, gender, social vulnerability, and urbanicity, with disparities in access and utilization. Despite increased ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...